KalVista Pharmaceuticals, Inc. - Common Stock (NQ:KALV)

15.49 -1.07 (-6.46%)

Streaming Delayed Price Updated: 4:00 PM EDT, Mar 18, 2026 Add to My Watchlist

Price and Volume

Volume	786,459
Open	16.68
Bid (Size)	15.49 (1,300)
Ask (Size)	15.50 (4,300)
Prev. Close	16.56
Today's Range	15.45 - 16.68
52wk Range	9.235 - 19.00
Shares Outstanding	34,233,643
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

What to Make of VR Adviser's Big Ocular Therapeutix Sell-Down ↗

Today 11:41 EDT

This ophthalmic biopharma firm develops sustained drug delivery therapies for eye diseases, targeting both U.S. and global markets.

Via The Motley Fool

KalVista Pharmaceuticals to Report Eight Months Fiscal Year 2025 Financial Results and Provide Corporate Update on March 25, 2026

Today 7:00 EDT

From KalVista Pharmaceuticals, Inc.

Via Business Wire

Performance

YTD	+0.2%	+0.2%
1 Month	+3.3%	+3.3%
3 Month	-2.6%	-2.6%
6 Month	+14.7%	+14.7%
1 Year	+24.0%	+24.0%

More News

VR Adviser Adds Over 1 Million Savara Shares ↗

March 15, 2026

Via The Motley Fool

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 04, 2026

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Presents New Data Highlighting High Patient Satisfaction and Evolving Treatment Trends with EKTERLY® (sebetralstat)

March 02, 2026

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals to Present at Upcoming Investor Conferences

February 25, 2026

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Announces Inclusion of EKTERLY® (sebetralstat) as a First-Line Therapy for Adolescents 12 and Older in International Pediatric HAE Guideline

February 18, 2026

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals to Present EKTERLY® (sebetralstat) Data at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting

February 12, 2026

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 03, 2026

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Stock Rallies After Hours On Strong Genetic Disorder Drug Sales Kickstart ↗

January 08, 2026

Via Stocktwits

Get insights into the top gainers and losers of Thursday's after-hours session. ↗

January 08, 2026

Via Chartmill

KalVista Pharmaceuticals Provides Update on Strong EKTERLY® Launch with Preliminary Fourth Quarter and Full Year 2025 Revenue Results

January 08, 2026

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Announces Approval of EKTERLY® (sebetralstat) in Japan, First and Only Oral On-demand Treatment for Hereditary Angioedema

December 22, 2025

From KalVista Pharmaceuticals, Inc.

Via Business Wire

These stocks are moving in today's session ↗

December 03, 2025

Via Chartmill

KalVista Pharmaceuticals Provides Operational Update and Reports Third Quarter Financial Results

November 10, 2025

From KalVista Pharmaceuticals, Inc.

Via Business Wire

Examining the Future: KalVista Pharma's Earnings Outlook ↗

November 10, 2025

Via Benzinga

KalVista Pharmaceuticals Presents New Data Highlighting Patient Satisfaction with EKTERLY® (sebetralstat) and its Potential in Children Ages 2-11 at the ACAAI 2025 Annual Scientific Meeting

November 06, 2025

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals to Present at Upcoming Investor Conferences

November 05, 2025

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals to Host Third Quarter Financial Results Conference Call and Webcast on November 11, 2025

November 03, 2025

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting

October 30, 2025

From KalVista Pharmaceuticals, Inc.

Via Business Wire

Ionis Pharmaceuticals (NASDAQ:IONS) Ascends to Six-Year High, Fueled by Breakthrough Pipeline and Robust Sales Outlook

October 08, 2025

Via MarketMinute

KalVista Pharmaceuticals Presents New Data Highlighting the Potential of EKTERLY® (sebetralstat) to Transform On-Demand Hereditary Angioedema Treatment in Europe

October 06, 2025

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Appoints Bilal Arif as Chief Operating Officer and Linea Aspesi as Chief People Officer

October 06, 2025

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 03, 2025

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Announces Appointment of Bethany L. Sensenig to Board of Directors

October 02, 2025

From KalVista Pharmaceuticals, Inc.

Via Business Wire

Frequently Asked Questions

Is KalVista Pharmaceuticals, Inc. - Common Stock publicly traded?

Yes, KalVista Pharmaceuticals, Inc. - Common Stock is publicly traded.

What exchange does KalVista Pharmaceuticals, Inc. - Common Stock trade on?

KalVista Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for KalVista Pharmaceuticals, Inc. - Common Stock?

The ticker symbol for KalVista Pharmaceuticals, Inc. - Common Stock is KALV on the Nasdaq Stock Market

What is the current price of KalVista Pharmaceuticals, Inc. - Common Stock?

The current price of KalVista Pharmaceuticals, Inc. - Common Stock is 15.49

When was KalVista Pharmaceuticals, Inc. - Common Stock last traded?

The last trade of KalVista Pharmaceuticals, Inc. - Common Stock was at 03/18/26 04:00 PM ET

What is the market capitalization of KalVista Pharmaceuticals, Inc. - Common Stock?

The market capitalization of KalVista Pharmaceuticals, Inc. - Common Stock is 530.28M

How many shares of KalVista Pharmaceuticals, Inc. - Common Stock are outstanding?

KalVista Pharmaceuticals, Inc. - Common Stock has 530M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.